RNF4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL9711326	0.46	2/20
SCHEMBL3382618	1.00	1/20
SCHEMBL6416827	0.79	1/20
SCHEMBL2000889	0.77	1/20
SCHEMBL201795	0.71	1/20
SCHEMBL2173035	0.71	1/20
SCHEMBL4262750	0.71	1/20
SCHEMBL9240178	0.71	1/20
SCHEMBL44662	0.70	1/20
Iodide (SCHEMBL998878)	0.68	1/20
Hydrochloric Acid (SCHEMBL9483678)	0.68	1/20
SCHEMBL3224230	0.68	1/20
SCHEMBL6689395	0.68	1/20
SCHEMBL2330263	0.67	1/20
SCHEMBL5452605	0.67	1/20
SCHEMBL7342035	0.67	1/20
SCHEMBL4653369	0.66	1/20
SCHEMBL9081388	0.66	1/20
SCHEMBL1289638	0.65	1/20
SCHEMBL9370053	0.64	1/20

Clinical trials — most relevant to RNF4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy	PHASE2	COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis	PHASE2	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease	EARLY_PHASE1	RECRUITING
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma	EARLY_PHASE1	RECRUITING
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer	EARLY_PHASE1	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome	nan	RECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)	nan	UNKNOWN
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome	nan	COMPLETED
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Establishment of a Prospective Clinical-biological Database	nan	RECRUITING
Prevention and Early Detection Biomarkers of Adenomas and CRC Lesions During CRC Screening	nan	COMPLETED
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With Hematuria	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RNF4 binder may also engage these)

Protein	Name	Similarity
Q9QZS2	—	0.996	Q9QZS2 →
O88846	—	0.993	O88846 →
Q9UT72	—	0.986	Q9UT72 →
P40072	—	0.982	P40072 →
O13826	—	0.979	O13826 →
Q6ZPS6	—	0.976	Q6ZPS6 →
Q9VB08	—	0.976	Q9VB08 →
Q58WW2	—	0.976	Q58WW2 →
P87176	—	0.976	P87176 →
P84445	—	0.976	P84445 →
Q5REL3	—	0.976	Q5REL3 →
Q2NNU1	—	0.975	Q2NNU1 →
Q5R9B8	—	0.975	Q5R9B8 →
P28990	—	0.974	P28990 →
Q8B9B2	—	0.974	Q8B9B2 →
Q9DC22	—	0.974	Q9DC22 →
Q9CZW6	—	0.974	Q9CZW6 →
Q7ZW16	—	0.973	Q7ZW16 →
Q96GF1	—	0.973	Q96GF1 →
Q6PIJ6	—	0.973	Q6PIJ6 →
Q5RFK9	—	0.973	Q5RFK9 →
Q6ASW7	—	0.973	Q6ASW7 →
Q568Y3	—	0.972	Q568Y3 →
Q8T3Y0	—	0.972	Q8T3Y0 →
Q91FJ2	—	0.972	Q91FJ2 →
Q2PFU6	—	0.972	Q2PFU6 →
Q9P3U8	—	0.972	Q9P3U8 →
Q91YT2	—	0.972	Q91YT2 →
Q1L8G6	—	0.972	Q1L8G6 →
D2H0Y8	—	0.971	D2H0Y8 →